Press Release

Myovant Sciences Announces Upcoming Presentation at Baird’s 2017 Global Healthcare Conference

31 Aug 2017 at 12:00 pm ET

PDF Version

BASEL, Switzerland, Aug. 31, 2017 /PRNewswire/ — Myovant Sciences (NYSE: MYOV), a leading clinical-stage biopharmaceutical company focused on women’s health and endocrine diseases, today announced that Lynn Seely, M.D., President and Chief Executive Officer, will present at Baird’s 2017 Global Healthcare Conference in New York City on September 7th at 12:15 p.m. Eastern Time.


The presentation and fireside chat will be webcast live and may be accessed via the Events page under the Investors and Media section of Myovant’s website at Please connect to the company’s website at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to listen to the webcast. A replay will also be available at the same location for 30 days following the conference.

About Myovant Sciences
Myovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women’s health and endocrine diseases. Myovant’s lead product candidate is relugolix, an oral, once-daily, small molecule that acts as a GnRH receptor antagonist. Myovant has initiated three clinical programs for relugolix consisting of five international Phase 3 clinical trials, two in women with heavy menstrual bleeding associated with uterine fibroids, two in women with endometriosis-associated pain, and one in men with advanced prostate cancer. Myovant is simultaneously developing MVT- 602, a kisspeptin agonist, for the treatment of female infertility as part of assisted reproduction. Over time, the company intends to expand its development pipeline to include other potential treatments for women’s health and endocrine diseases. For more information, please visit the company’s website at

Investor Contact:
Frank Karbe
Chief Financial Officer
Myovant Sciences, Inc.

Media Contact:
Julie Normart
Pure Communications


View original content with multimedia:

SOURCE Myovant Sciences, Ltd.

Source: Myovant Sciences, Inc.